(Q39865068)

15 September 2017

title

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo (English)

1 reference

15 September 2017

1 reference

Michael Pohl

1

1 reference

15 September 2017

I Stricker

2

1 reference

15 September 2017

A Schoeneck

3

1 reference

15 September 2017

K Schulmann

4

1 reference

15 September 2017

S Klein-Scory

5

1 reference

15 September 2017

I Schwarte-Waldhoff

6

1 reference

15 September 2017

M Hasmann

7

1 reference

15 September 2017

A Tannapfel

8

1 reference

15 September 2017

W Schmiegel

9

1 reference

15 September 2017

A Reinacher-Schick

10

1 reference

15 September 2017

publication date

2 April 2009

1 reference

Journal of Cancer Research and Clinical Oncology

15 September 2017

published in

1 reference

15 September 2017

volume

135

1 reference

15 September 2017

issue

10

1 reference

15 September 2017

page(s)

1377-1386

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-009-0579-3

15 September 2017

exact match

0 references

cites work

The HER-2/neu oncogene in tumors of the gastrointestinal tract

1 reference

12 December 2020

Preclinical studies with Erlotinib (Tarceva).

1 reference

12 December 2020

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

1 reference

12 December 2020

Epidermal growth factor

1 reference

12 December 2020

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

1 reference

12 December 2020

Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer

1 reference

12 December 2020

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

1 reference

12 December 2020

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

1 reference

12 December 2020

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

12 December 2020

ErbB family targeting.

1 reference

12 December 2020

Preclinical and clinical trials of topoisomerase inhibitors

1 reference

12 December 2020

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

1 reference

12 December 2020

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

12 December 2020

Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation

1 reference

12 December 2020

Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines

1 reference

12 December 2020

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

1 reference

12 December 2020

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

1 reference

12 December 2020

Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells

1 reference

12 December 2020

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

12 December 2020

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

12 December 2020

High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters

1 reference

12 December 2020

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

12 December 2020

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

12 December 2020

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67

1 reference

12 December 2020

Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia.

1 reference

12 December 2020

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

12 December 2020

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

1 reference

12 December 2020

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer

1 reference

12 December 2020

Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

12 December 2020

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

1 reference

12 December 2020

10.1007/S00432-009-0579-3

Identifiers

DOI

1 reference

15 September 2017

1 reference